Been at this almost 30 yrs. Finding biofrauds is not difficult but making money on their inevitable demise is tricky (much harder than longs). Someone told me this long ago that some biofrauds are shorts/puts BEFORE data readouts and some are AFTER. In retrospect $CAPR was a short AFTER and I suspect $SLS might be also. Some management teams just don't have the integrity to actually admit that their data set failed on the topline readout but the FDA almost always sniffs out the failures. Tiny exceptions where placebo makes it to market ($SRPT).
Binaries can be exiting but also gut wrenching. I went through a period long ago where I completely avoided binaries for years but I have gotten numb to gains/losses so I still do it today. Yes, I made half a million on the COVID vaccine readout binary in 2020 ($BNTX) but lost $120k on puts/shorts of a deliberate fraud last year ($CAPR). Was right on both but lost money on one. None of this affects the day to day life of my family. I reminded the wife today that I was right about that trial last year where I lost $$, she didn't even remember it 🤣🤣🤣 inconsequential to her.
4
510
As far as $ABVX drama, I don't think the short report affects the company long term. Usually these reports cause a short term crash and recovery. I avoided both of the 2026 Abivax crashes because I already liquidated this big winner (50 ->120) at the end of 2025 to cover my large $CAPR loss on the fake readout and short squeeze. That has been the theme of 2025/2026, win/loss/win/loss. Even when I have been correct have sometimes lost money: exhausting.
12
912
FDA is saying the trial was fraudulent: $CAPR. They rarely are this blunt.
"The correspondence identifies serious data integrity violations in the conduct of Study HOPE-3 that cannot be remediated post-hoc."
"Among the deficiencies identified in the CRL, is that serious clinical trial data integrity deficiencies identified in Study HOPE-3 render the study data unreliable and incapable of post hoc remediation."
Capricor and @MarbanLab at Cedars-Sinai are both frauds. Despicable.
Updated data from $PMVP. Jittery market, stock down 40%. No, don't own this but data is consistent with prior data cuts not sure why crashing. Been following closely but main concern is the same, rare mutation, tiny market to commercialize.
The cohort-specific ORRs were as follows:
Ovarian cancer: 45% ORR (45/101 patients, including four confirmed CRs, 37 confirmed PRs, and four uPRs)
Lung cancer: 21% confirmed ORR (4/19 patients)
Breast cancer: 17% confirmed ORR (3/18 patients)
Endometrial cancer: 45% confirmed ORR (5/11 patients)
Other solid tumors: 21% confirmed ORR (4/19 patients)
Rezatapopt data looks excellent for $PMVP. IMO an approvable drug. My main concerns are small market for this Y220C mutation, this is like 250-350 pts/yr in USA. Assuming usual pricing, about $30M/yr. Need to find other indications. Short term have predatory offering terms and long term won't be profitable with this run rate.
The fact that Edgewise $EWTX was able to unload this asset onto Servier for $1.55 billion in cash upfront with a obviously predictable fail is mind boggling to me. Since these morons bought it, I was unable to make money from this fail.
Healthcare also. Hitting the lowest paid workers first. For ex just today, did surgery on a lady last week, she applied for disability coverage, AI agent called my office, my nurse answers, AI agent had all pt info, interacted with nurse over phone, then generated a confirmation fax, sent fax to me to sign, I signed it, faxed back. Disability coverage approved. AI replaced an office worker at the medical disability co. So much back office medical staff going to be deleted due to AI. Will still need some but far fewer.
Re-tried "Ask Doximity AI tool" recently and it is quite good. As good or better than OpenEvidence. Good for researching less common operations/consultations. Not good for market based research since the AI models for both are not set up on latest press releases from biotechs. $DOCS
Replying to @WaterworldCapi1
OpenEvidence already killing off $DOCS first. Already uninstalled Doximity app. Had it for years. Little to no use now.
2
8
1,849
Really good mouse data after pivoting to GalNAc delivery from prior whiff using LNP. But up 30% on 🐁 data is a bit much. A therapy to watch in the future. No position. $KRRO
New preclinical data for KRRO-111 reduced pathogenic Z-AAT in the liver by up to 95%, supporting its potential to address both lung and liver manifestations of #AATD. Regulatory submission expected in H1 2027.
Learn more: bit.ly/4yDFEjt $KRRO
5
1,016
Nice tuck in acquisition. $PCRX sales have been pretty mature and stable despite Federal and state opiate initiatives. We currently pay about $220 a bottle for Exparel, I just hope Viatris doesn't jack up the prices after the buyout. Good for tummy tucks, etc. Competition from Zynrelef never materialized $HRTX. Probably because of the gooey sticky consistency. Didn't trust it if I use drains, used in most plastic surgery procedures.
11
1,293
One thing I have noticed since getting back into active investing in 2020: thematic based market trends significantly overshoot and undershoot your expectations. COVID vaccine, post COVID opening trash, GLP winners/losers, and now AI drug discovery ($TWST is the best example). At the end of all of these thematic trades, the tickers broaden out to lower quality names (e.g. $DNA). Calling a top or bottom is difficult in real time, but some catalyst always marks a change in sentiment.
Grail Adcom briefing docs are up. No time to analyze it this morning but the stock is ripping $GRAL
Voting Question 1:
Is there reasonable assurance that Galleri is safe for patients who meet the criteria specified in the proposed
indication?
Voting Question 2:
Is there reasonable assurance that Galleri is effective for use in patients who meet the criteria specified in the
proposed indication?
Voting Question 3:
Do the benefits of Galleri outweigh the risks for use in patients who meet the criteria specified in the proposed
indication?
4
9
2,952
For buy+hold guy at heart, $XENE posed problems for me. I played the FOS readout in March, but sold right after since the MDD/BPD readouts were super high risk (coin flip odds). It didn't even pop that much for the FOS success (mostly priced in, but made decent $). Prob FDA approval baked in for FOS as well (likely flat on approval imo). So, now the MDD program zeroed out for random safety issue, would the stock trade down again on a MDD fail in 1/2027? Also, commercial launch is murky since so many damn generics in this space.
Rezatapopt data looks excellent for $PMVP. IMO an approvable drug. My main concerns are small market for this Y220C mutation, this is like 250-350 pts/yr in USA. Assuming usual pricing, about $30M/yr. Need to find other indications. Short term have predatory offering terms and long term won't be profitable with this run rate.







